Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by Nailbiter2on Jan 30, 2024 4:53pm
124 Views
Post# 35853609

Roarin' Rory

Roarin' Rory

Rory Balfour Riggs

Independent Director, StageZero Life Sciences Ltd.

Founder of 12 different companies, notably: Royalty Pharma Plc, Cibus, Inc. and FibroGen, Inc. Rory Balfour Riggs is an entrepreneur and businessperson who has been at the head of 15 different companies and is Chairman & CEO (Co-founder) at Cibus Corp. (which he founded in 2001), Chairman of Cibus Ltd. and Chairman for Nucelis, Inc. (both are subsidiaries of Cibus Corp.), Chairman & Chief Executive Officer at Cibus, Inc. (which he founded), Executive Chairman (Founder) at Syntax LLC (since 2009), Chief Executive Officer & Trustee at Syntax ETF Trust, CEO (Founder) at Locus Analytics LLC (which he founded in 2010) and Chief Executive Officer at Syntax Advisors LLC (which he founded) (which are all subsidiaries of Syntax LLC), Chief Executive Officer at Syntax Analytics LLC (which he founded in 2010) and General Partner for Scientia Ventures LLC (which he founded in 2006). He is also Managing Member at Balfour Venture Partners and on the board of 5 other companies.

Mr. Riggs previously occupied the position of Managing Member at Balfour LLC, Director at eReceivables Inc. (he founded the company in 2003), President & Chief Executive Officer of The RF&P Corp., Associate at Strategic Planning Associates, President, Chief Financial Officer & Director at Biomatrix, Inc., Managing Member at New Ventures I LLC, Managing Director at PaineWebber, Inc., Principal at Pacific Media Partners, Inc., Chairman/Director at Sugen, Inc. and Board Member (Co-founder) at FibroGen, Inc.

Mr. Riggs received an undergraduate degree from Middlebury College and an MBA from The Trustees of Columbia University in The City of New York.

<< Previous
Bullboard Posts
Next >>